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Abstract
Background: H. pylori infection may trigger Smad7 and NFB expression in the stomach, whereas probiotics
promote gastrointestinal health and improve intestinal inflammation caused by pathogens. This study examines if
probiotics can improve H. pylori-induced gastric inflammation by inactivating the Smad7 and NFB pathways.
Results: Challenge with H. pylori increased IL-8 and TNF-a expressions but not TGF-b1 in MKN45 cells. The RNA
levels of Smad7 in AGS cells increased after H. pylori infection in a dose-dependent manner. A higher dose (MOI
100) of L. acidophilus pre-treatment attenuated the H. pylori-induced IL-8 expressions, but not TGF-b1. Such anti-
inflammatory effect was mediated via increased cytoplasmic IBa and depletion of nuclear NFB. L. acidophilus
also inhibited H. pylori-induced Smad7 transcription by inactivating the Jak1 and Stat1 pathways, which might
activate the TGF-b1/Smad pathway. L. acidophilus pre-treatment ameliorated IFN-g-induced Smad7 translation level
and subsequently reduced nuclear NF-B production, as detected by western blotting.
Conclusions: H. pylori infection induces Smad7, NFB, IL-8, and TNF-a production in vitro. Higher doses of
L. acidophilus pre-treatment reduce H. pylori-induced inflammation through the inactivation of the Smad7 and
NFB pathways.
Background
Helicobacter pylori infection is considered a major factor
inducing chronic gastritis, peptic ulcer, and even gastric
cancer in humans [1-3]. In mice and human studies,
the gastric mucosa of H. pylori-infected subjects show
up-regulated NF-B pathway and Th1 type cytokine
responses [4-9], which may disturb the integrity of the gut
epithelial barrier [10]. Accordingly, the inactivation of the
NF-B pathway and its downstream immune cascades
may be helpful in preventing serious H. pylori-induced
complications.
Probiotics are known to inhibit enteric pathogens likes
Salmonella, Shigella,a n dCitrobacter rodentium in both
in vitro and animal models [11-13]. Their potential clini-
cal benefits in preventing or resolving gastrointestinal
diseases have been emphasized [14,15]. There are several
mechanisms through which they provide gut protection,
including decreasing the luminal pH value by producing
lactic acid [16,17] or by competing with gut pathogens
for host surface receptors [18].
Nonetheless, Coconnier et al. have shown that probio-
tics may inhibit H. pylori growth independent of pH and
lactic acid levels [19] while Tien et al. report that Lacto-
bacillus casei may down-regulate Shigella flexneri-
induced pro-inflammatory cytokines, chemokines, and
adherence molecules by inhibiting the NF-B pathway
[12]. Another critical mechanism involving probiotics
relates to changes in host immune responses to infection
via reduced TNF-a and IL-8 but increased IL-10 [20,21].
Regarding the brief contact between the flora of probio-
tics and the gastric epithelium, an intake of probiotics by
H. pylori-infected patients has anti-inflammation benefits
resulting from a change in host immune responses.
Transforming growth factor (TGF)-b1 negatively regu-
lates Th1 cell such that TGF-b1/deficient mice sponta-
neously develop gastritis [22,23]. It is well accepted that
the TGF-b1 signaling pathway is positively regulated by
receptor-associated Smad 2/3, but negatively by Smad7
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any medium, provided the original work is properly cited.[24,25]. H. pylori infection is reportedly associated with
increased expression of gastric Smad7, but controversial
results in TGF-b1 levels [26,27]. These suggest that the
TGF-b1/Smad signaling pathway plays an important role
in gut inflammation. However, the exact mechanism of
probiotics reducing H. pylori-induced gastric inflamma-
tion remains unclear. Thus, this study aimed to examine
whether probiotics could regulate the Smad- and NFB-
mediated signaling pathways to reduce the down-stream
inflammatory cytokine production after H. pylori
infection.
Methods
Cell lines and culture condition
This study was approved by the Ethical Committee of
National Cheng Kung University Hospital (ER-98-208).
Two human gastric epithelial cancer cell lines (MKN45
and AGS) were obtained from the Health Science
Research Resources Bank in Japan and maintained in
RPMI 1,640 medium (GIBCO BRL, Grand Island, NY)
and F-12 medium (GIBCO BRL, Grand Island, NY) con-
taining 10% FBS at 37°C in a humidified atmosphere (95%)
with 5% CO2. The cells were sub-cultured every second
day. Prior to the bacterial infection study, the cells were
incubated in antibiotic-free RPMI 1,640 medium contain-
ing 10% FBS overnight at 37°C in 5% CO2.
Bacteria and culture condition
Bacterial strain (HP238) isolated from a clinical patient
was used. The HP238 expressed CagA, VacA, and BabA
proteins in previous studies [28,29]. The bacteria were
maintained on a Brucella agar plate containing 10% horse
serum and incubated under micro-aerophilic conditions
(10% CO2,5 %O 2 and 85% N2) for 24-48 hours. The bac-
teria were then transferred toP B Sb e f o r ei n f e c t i n gt h e
cells. Growth density was measured spectrophotometri-
cally at 600 nm. The infectious dose of bacteria was 1 ×
10
8 bacteria/ml at an OD of 1.
The MKN45 cells were infected with a multiplicity of
infection (MOI) 1-100 for various time periods. A probiotic
strain, one contained in AB-yogurt, Lactobacillus acidophi-
lus (LA5
®, originated from the Chr. Hansen, Denmark,
provided by the President Corp., Tainan, Taiwan) was
used. The bacteria were maintained on a Brucella agar,
incubated in anaerobic conditions, and then harvested and
suspended in phosphate-buffered saline (PBS) before infec-
tion. The viable density of L. acidophilus was 1 × 10
8 bac-
teria/ml at an OD of 1.
MKN45 cells viability after exposure to H. pylori and
L. acidophilus
The cytotoxicity of MKN45 cell exposure to H. pylori and
L. acidophilus was determined by percentage of lactate
dehydrogenase (LDH) leakage (Cytotoxicity Assay,
Promega Co., Madison, WI, USA) and by assessing viable
cell counts using non-stained trypan blue. The culture
supernatant and remaining MKN45 cells were collected
after incubation with variable doses (MOI 1-1000) of
L. acidophilus and H. pylori (MOI 100) for 8 and 4 hours,
respectively. Cell cultures without bacterial infection
served as controls. The procedures were performed
according to the instruction manuals and post-infection
cells with non-stained trypan blue staining were directly
counted.
Enzyme-linked immuno-sorbent assay (ELISA) for
cytokines
To determine the optimal dose and incubation time of
various bacteria, bacteria (H. pylori and L. acidophilus)
were cultured with MKN45 cells (MOI 1-100) in an anti-
biotic-free RPMI 1,640 medium (5 ml) containing 10%
FBS at 35°C in micro-aerophilic conditions for up to
8 hours. In the experimental study, L. acidophilus were
added to MKN45 cells and incubated for 8 hours under
the same conditions. After PBS washing and removal of
the bacilli, an equal volume of H. pylori was added and the
cells were incubated for another 4 hours. The final culture
supernatant was centrifuged at 12,000 rpm for 5 min to
remove bacteria and cell debris. Concentrations of TNF-a,
IL-8 (R & D System, Minneapolis, MN), and TGF-b1
(eBioscience, San Diego, CA) were measured by ELISA
according to the manufacturer’s instructions. The absor-
bance of each micro-plate was read on a spectro-photo-
meter using 450 nm as the primary wave length and 570
nm as the reference wave length. All tests were done in
triplicate.
Preparation of cytoplasmic and nuclear extracts
The MKN45 and AGS cells were pre-treated with
L. acidophilus for 8 hours followed by various doses of
H. pylori for 1 hour; then cytoplasmic and nuclear
extracts were isolated by a Nuclear Extract Kit (Active
Motif, Japan). Briefly, cells were washed with ice-cold
saline containing phosphatase inhibitors and pelleted.
The cell pellets were then re-suspended in a hypotonic
buffer and incubated for 15 min on ice. They were lysed
by the addition of detergent and vortexed vigorously for
10 s. After the nuclei were pelleted and re-suspended in
complete lysis buffer, the tube was vigorously shaken at
4°C for 30 min on a shaking platform. The nuclear
extracts were then centrifuged and the supernatants
were aliquoted and stored at -80°C.
RT-PCR for cytoplasmic Smad7
Total RNA was isolated from MKN45 cells using a com-
mercial kit (ImProm-ll™ Reverse Transcription System,
Promega, USA) after H. pylori and L. acidophilus incuba-
tion. The RNA was quantified by determining absorbance
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was stored at -72°C until use. The human Smad7 primer
sequences were forward 5’-CATCACCTTAGCC-
GACTCTG-3’ and reverse 5’GTCTTCTCCTCCCAG-
TATGC-3’, generating a 224 bp fragment [30]. For Jak1
and Stat1, the primer sequences were forward 5’-GCAGC-
CAGCATGATGAGA-3’ and 5’-GTGGACGAGGTTTTG-
TAAGGA-3’ and reverse 5’-CTCGGAAGAAAGGCCT
CTG-3’ and 5’-CAGACACAGAAATCAACTC-3’, gener-
ating fragments of 607 bp and 518 bp, respectively [31,32].
The PCR condition was as follows; 95°C for 5 min, fol-
lowed by 25 cycle of 95°C for 1 min, 56°C for 1 min, and
72°C for 1 min, and finally 72°C for 7 min. The primer
sequences for human b-actin was forward 5’-GTCTTCCC
CTCCATCGTG-3’ and reverse 5’-GTCATCTTCTCGC
GGTTG-3’, generating a 272 bp fragment. The amplifica-
tion conditions were as follows: 95°C for 5 min, then a
20 cycle of 95°C for 1 min, 50°C for 1 min, 72°C for 1 min,
and 72°C for 7 min.
Western blotting for NF-B, IB-a and Smad7
Interferon gamma (IFN-g) (PeproTech Inc., NJ, USA)
50 μl (100 ng/ml) was added to each dish in the experi-
mental studies. The cytoplasmic and nuclear extracts
were washed with ice-cold PBS and lysed in a 0.5 ml/
well lysis buffer (150 mmol/l NaCl, 20 mmol/l Tris, pH
7.5, 0.1% Triton X-100, 1 mmol/l phenylmethylsulfonyl
fluoride [PMSF] and 10 μg/ml aprotonin) as modified
f r o mt h er e p o r t so fK i me ta l .a n dM o o ne ta l .[ 3 3 , 3 4 ] .
Protein concentrations in the lysates were determined
using the Pierce BCA Protein Assay Kit (Thermo scien-
tific, USA). Protein/lane 10 μg was then size-fractionated
into a denaturing, non-reducing 10% polyacrylamide
minigel and electrophoretically transferred to polyvinyli-
dene fluoride (PVDF) (0.45-μm pore size) (Millpore
Corparation, USA).
Specific proteins were detected using rabbit antihuman
NF-B p65, rabbit anti-human IB-a (1:1000, Cell Signal-
ing, Boston, MA, USA), and mouse anti-human Smad7
( 1 : 5 0 0 ,R & DS y s t e m ,U S A ,M N )a sp r i m a r ya n t i b o d i e s ,
and peroxidase-conjugated anti-rabbit IgG, anti-mouse
IgG (1:10000) as a secondary antibody. Specifically bound
peroxidase was detected by Chemiluminescent HRP Sub-
strate (ECL system, Millpore Corparation, USA) and then
exposed to x-ray (GE Healthcare, UK) for 10-30 s.
Statistical analysis
The Student’s t test and paired t test were used, as appro-
priate, for parametric differences. One-way analysis of var-
iance (ANOVA) with Bonferroni’s correction was applied
for the multiple testing of data. The Mann-Whitney U test
was used for the difference between non-parametric data
while Pearson’s c2 test was used for non-parametric
proportion difference. All tests were two-tailed and a P <
0.05 was considered statistically significant.
Results
Cell viability after incubation with H. pylori and L.
acidophilus
The cytotoxicity and viability of MKN45 cells incubated
with H. pylori (MOI 100) and L. acidophilus (MOI 1-
1000) were determined by assessing the percentage leak-
age of LDH and non-stained trypan blue at the 4
th and
8
th hours, respectively (Table 1). Plasma membrane
damage assessed by the percentage of LDH leakage
from MKN45 after H. pylori incubation (18.1%) was not
different to those of control cells (18.0%). Moreover, the
viable cell count calculated by non-stained trypan blue
did not markedly decrease. When L. acidophilus was
incubated with MKN45 cells for 8 hours, the cytotoxi-
city and viable cell count at MOI 1-100 were not signifi-
cantly affected. However, LDH leakage and cell death
slightly increased as incubation with MOI 1,000 for
8 hours. Therefore, the optimal dose of bacteria used
for the experimental study was limited to MOI 100.
H. pylori stimulated IL-8 and TNF-a but not TGF-b1
production in vitro
In MKN45 cells incubated with H. pylori (MOI 100) at
various time periods, the IL-8 level increased from the 4
th
to the 8
th hour after co-incubation, as determined by
ELISA (Figure 1A). For TNF-a, the post-incubation level
rose after the 4
th hour and maintained a plateau until the
8
th hour (Figure 1B). However, the TGF-b1 level did not
increase after H. pylori incubation for 4 hours (data not
shown).
In contrast, L. acidophilus did not induce IL-8, TNF-
a,a n dT G F - b1 expressions of MKN45 at least within
the 8-hour co-incubation period.
Table 1 Cell cytotoxicity and viable cell counts of MKN45
after co-incubation with H. pylori and L. acidophilus
determined by the percentage of LDH leakage (in
triplicate) and non-stained trypan blue (single)






Cell only for 4 and 8
hours
18.0, 18.0 1.36
H. pylori for 4 hours
MOI 100 18.1 1.00
Lactobacillus for 8 hours
MOI 1 18.4 1.00
MOI 10 18.0 1.11
MOI 100 18.7 1.24
MOI 1000 24.2 0.77
aAll cytotoxicity data were presented with mean value of three tests
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induced IL-8
Because the IL-8 level of MKN45 cells could be induced
by H. pylori challenge for 4 hours, the time- and dose-
dependent effects of probiotics in reducing pro-inflam-
matory cytokines and TGF-b1o nt h e4
th hour were stu-
died. The IL-8 and TGF-b1 concentrations were shown
for MKN cells challenged by H. pylori and with variable
Figure 1 (A) IL-8 and (B) TNF-a concentrations in the supernatant of MKN45 cells culture after variable duration of H. pylori and L.
acidophilus infection (MOI = 100). Data were expressed as means ± standard deviation (SD) (in triplicate).
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Compared to the control group, L. acidophilus pre-treat-
ment with higher bacterial colony count (MOI 100)
reduced H. pylori-induced IL-8 expressions in MKN45
cells (P < 0.05). The TGF-b1 level did not change (P >
0.05).
L. acidophilus reduced H. pylori-induced NF-Bb y
increasing IBa
The study determined that MKN45 cells (MOI 100) incu-
bated with H. pylori led to a peak increase of nuclear NF-
B production within one hour. Thus, nuclear NF-B
levels of MKN45 cells co-incubated with H. pylori,a f t e r
prior pre-treatments by various MOIs (1-100) of L. acido-
philus were tested for anti-inflammatory effects of probio-
tics. Pre-treatment of L. acidophilus increased cytoplasmic
IBa but decreased the nuclear NF-B levels induced by
H. pylori in a dose-dependent manner (Figure 3). Because
IBa level could be mediated by activating the TGF-b1/
Smad signaling pathway, the role Smad7 played in L. acid-
ophilus restoring TGF-b1/Smad activity after H. pylori
challenge was tested.
L. acidophilus inhibited H. pylori-and IFN-g-induced Smad7
expression
The Figure 4A shows that pre-treatment with high-dose
L. acidophilus (MOI 100) for 8 h prevented H. pylori-
induced Smad7 production by semi-quantitative RT-PCT.
Compared to positive controls (AGS cells co-incubated
with H. pylori at MOI 100), L. acidophilus pretreatment as
high as MOI 100 significantly reduced the H. pylori-
induced Smad7 production at the RNA level (P < 0.05) via
inactivation of Jak1 and Stat1 transcriptions. L. acidophilus
pre-treatment also inhibited the expression of IFN-g-
induced Smad7 protein (P < 0.05) in vitro,w i t ha
subsequent increase in cytoplasmic IBa (P < 0.01) and a
decrease in nuclear NF-B( P < 0.01) (Figure 4B).
Discussion
Human immunity plays an important role in the develop-
ment of more serious clinical diseases after H. pylori infec-
tion because of increased pro-inflammatory cytokine
expressions on the patients’ gastric mucosa [6,8]. H. pylori
infection can activate NF-B in gastric epithelium cells
and subsequently up-regulate IL-8 gene transcription [4].
Consistent with previous human studies [6-9], the present
study reveals that H. pylori infection can induce TNF-a
and IL-8 pro-inflammatory cytokine expressions in vitro.
In agreement with the animal study reported by McCarthy
et al. [35], the present study illustrates that yogurt-contain-
ing probiotics, L. acidophilus does not stimulate pro-
inflammatory cytokines after an 8-hour incubation
with MKN45 cells. This suggests that probiotics can exert
anti-inflammatory effects in vitro. Accordingly, it will be
interesting to test how the inflammatory cascades can be
counteracted by probiotics.
The antimicrobial activity of Lactobacillus against
enteric pathogens is, in part, due to the accumulation of
lactic acid [17,21]. The ability of lactic acid production
varies in the Lactobacillus spp.a n dL. acidophilus is a
low lactic acid-production strain [34]. Experimentally,
L. acidophilus decreases the viability of H. pylori in vitro
independent of pH and lactic acid levels [19]. The pH
value of each suspension in this study is around 6.8-7.0
(data not shown). Other mechanisms like immuno-
modulation should therefore contribute largely to the
anti-inflammatory effects of L. acidophilus.
The current study demonstrates that L. acidophilus
pre-treatment can decrease the H. pyloriinduced nuclear
NF-B expression in the 1
st hour and IL-8 in the 4
th
Figure 2 The concentrations of IL-8 (blank column) and TGF-b1 (black column) in the supernatant of MKN45 cells pre-treated with
different MOI (0: control; 1: 1 × 10
6 c.f.u.; 10: 1 × 10
7 c.f.u.; 100: 1 × 10
8 c.f.u.) of L. acidophilus. The cells were washed thrice with PBS to
remove the L. acidophilus and then infected with H. pylori (MOI = 100) for 4 hours. Data are expressed as means ± SD (in triplicate). Statistical
analysis was performed in each measurement with comparisons to the controls (cells treated H. pylori only; IL-8 2034 ± 865 pg/ml and TGF-b1
587.2 ± 39.8 pg/ml) (*P < 0.05).
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Furthermore, the TNF-a level is also decreased although
its value is quite low (data not shown). This study
further confirms that such suppression occurs in a dose-
dependent manner and is mediated through the stabili-
zation of IBa. The finding is compatible with the
results of Tien et al. showing that anti-inflammatory
effects can only be achieved at an adequate bacteria
count in probiotics [12]. Data from the present study
indicate that L. acidophilus can counteract H. pylori-
induced gastric inflammation specifically by mediation
through the IBa/NF-B pathway in a dose-dependent
manner.
In normal intestinal mucosal cells, the TGF-b1s i g n a l
may negatively regulate NF-B activation by stimulating
the negative regulator, IBa [36]. H. pylori infection
reportedly may inhibit the TGF-b1 signal pathway via
activation of the gastric Smad7 expression [26]. This
study also declares that both H. pylori and L. acidophilus
do not affect the TGF-b1 production of gastric epithelial
cells, which again confirm that L. acidophilus regulates
TGFb1/Smad3 downstream activity by restoring Smad7.
The present study is the first to demonstrate that L. acid-
ophilus can down-regulate Smad7 production to restore
the TGFb1/Smad activity and to ameliorate the H. pylori-
induced gastric inflammation in vitro (Figure 5).
Smad7 can also be induced in normal gastric specimens
by IFN-g through a STAT1 dependent pathway [26]. In
fact, the gastric epithelium does not secret IFN-g. There-
fore, H. pylori (up-regulation) and L. acidophilus (down-
regulation) both significantly regulates Smad7 in epithe-
lium cells through the mediation of the STAT1-dependent
Figure 4 Pre-treatment of L. acidophilus significantly reduced JAK1 (MOI 1-100), STAT1 (MOI 10-100), and SMAD7, and subsequent
NFB production after (A) H. pylori and (B) IFN-g treatment. N, AGS cell only; P, H. pylori, MOI = 100 (A, black column) and 100 ng/ml IFN-g
(B, black column) treatment for 0.5 hour; MOI 1, 10, and 100 meant pre-treatment with L. acidophilus 1×1 0
6,1×1 0
7,1×1 0
8 c.f.u. for 8 hours,
respectively, followed by H. pylori treatment for 0.5 hour (* P < 0.05; ** P < 0.01).
Figure 3 The IBa and NFB expressions after various doses of L. acidophilus pretreatment for 8 hours followed by H. pylori co-
incubation for 1 hour. N, MKN45 cell only; P, H. pylori,1×1 0
8 c.f.u. treatment for 1 hour; MOI 1, pre-treatment with L. acidophilus 1×1 0
6 c.f.u.
for 8 hours followed by H. pylori treatment for 1 hour; MOI 10, L. acidophilus 1×1 0
7 c.f.u. followed by H. pylori treatment for 1 hour; MOI 100, L.
acidophilus 1×1 0
8 c.f.u. followed by H. pylori treatment for 1 hour (*P < 0.05).
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b1/Smad3 signaling and result in the suppression of
inflammatory cytokine production in patients with inflam-
matory bowel diseases [37,38]. The data here reveals that
probiotics contained in yogurt can inhibit Smad7 to
diminish H. pylorirelated gastric inflammation. Such pro-
biotics can be quite promising for the improvement of
H. pylori infection control.
Conclusions
Yogurt-containing L. acidophilus can improve H. pylori-
induced gastric inflammation through the inactivation of
the Smad7 and NF-B mediated pathways. Intake of
L. acidophilus-containing yogurt may improve gastric
inflammation in H. pylori-infected patients.
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